What was the year‑over‑year growth rate for Q2 2025 revenue compared to Q2 2024?

Year‑over‑Year Growth Rate

The press release states that Q2 2025 revenue was $15.0 million, but it does not disclose the comparable Q2 2024 revenue figure. Without the prior‑year amount, the exact year‑over‑year (YoY) growth percentage cannot be calculated from the information provided. (For reference, the YoY growth rate would be calculated as [(Q2‑2025 – Q2‑2024) ÷ Q2‑2024 × 100 %]).

Trading Implications

• Fundamental View: The $15 M top‑line figure is modest for a publicly‑traded medical‑device company, and the lack of disclosed prior‑period data suggests either a flat/declining performance or a strategic decision not to highlight a weaker comparative quarter. Investors should seek the prior‑year revenue from the company’s SEC filing (10‑Q) or earnings call transcript to assess momentum.
• Technical Outlook: With limited fundamentals, technical analysis becomes key. If the stock has been trading near its 50‑day moving average and volume is modest, a breakout above recent resistance (e.g., the prior high) could signal bullish sentiment despite the unknown YoY growth. Conversely, failure to clear that level may indicate weakness.
• Actionable Insight: Wait for the full earnings release (including the Q2 2024 figure) before taking a position. In the meantime, monitor the stock’s price action for breakout/breakdown patterns, watch the 20‑day and 50‑day moving averages, and compare the $15 M revenue against the company's historical revenue trajectory to gauge whether the quarter reflects a trend or an outlier. If the upcoming data shows robust YoY growth (e.g., >10 %), consider a long‑biased stance; if growth is flat or negative, a short‑biased or neutral stance may be more prudent.